For what it is worth @Moneymaker1979 , I agree that Novartis...

For what it is worth @Moneymaker1979 , I agree that Novartis will commit to a partnership. The data will show the value, and a therapy that works and has little or no side effects are rare it would seem. Where or what I am trying to get my head round is whether what we do is regenerative. I maybe defining it wrong, but recent results seem to show we don’t regenerate, discs or heart muscles. What we are is an anti inflammatory therapy. By reducing inflammation we enable the body to heal or maintain in the case of the heart trial. It is why early Crohns/colitis trials have been so spectacular. The key is the “sweet spot” when it comes to the best results. Look there are better posters than me. Hopefully they and you will make your case on the same thread The Investment case for Mesoblast for easy reference for learning by number people like me and new investors who will shortly come flocking.
Meanwhile let’s enjoy the wait (somehow)
regards
Yelrom